Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.

Kimbung S, Biskup E, Johansson I, Aaltonen K, Ottosson-Wadlund A, Gruvberger-Saal S, Cunliffe H, Fadeel B, Loman N, Berglund P, Hedenfalk I.

Cancer Lett. 2012 Jun 28;319(2):232-41. doi: 10.1016/j.canlet.2012.01.015. Epub 2012 Jan 20.

PMID:
22266096
[PubMed - indexed for MEDLINE]
2.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

PMID:
22915752
[PubMed - indexed for MEDLINE]
3.

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.

Sun Y, Ding H, Liu X, Li X, Li L.

Tumour Biol. 2014 May;35(5):4469-77. doi: 10.1007/s13277-013-1589-y. Epub 2014 Jan 14.

PMID:
24420152
[PubMed - indexed for MEDLINE]
4.

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.

Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.

PMID:
22915751
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
[PubMed - indexed for MEDLINE]
6.

Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.

Wang X, Liu L, Montagna C, Ried T, Deng CX.

Cell Death Differ. 2007 May;14(5):924-31. Epub 2007 Feb 23.

PMID:
17318223
[PubMed - indexed for MEDLINE]
Free Article
8.

Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.

Sasaki A, Tsunoda Y, Tsuji M, Udaka Y, Oyamada H, Tsuchiya H, Oguchi K.

Anticancer Res. 2014 Sep;34(9):4893-7.

PMID:
25202071
[PubMed - indexed for MEDLINE]
9.

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.

Int J Biol Sci. 2006;2(4):179-85. Epub 2006 Jun 10.

PMID:
16810332
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.

Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH.

Oncogene. 2005 May 5;24(20):3285-96.

PMID:
15735702
[PubMed - indexed for MEDLINE]
11.

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Shibata H, Miuma S, Saldivar JC, Huebner K.

Cancer Sci. 2011 Oct;102(10):1882-8. doi: 10.1111/j.1349-7006.2011.02016.x. Epub 2011 Jul 21.

PMID:
21707865
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

PMID:
18971340
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
[PubMed - indexed for MEDLINE]
14.

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.

Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W.

Int J Oncol. 2014 Mar;44(3):735-44. doi: 10.3892/ijo.2013.2240. Epub 2013 Dec 31.

PMID:
24378347
[PubMed - indexed for MEDLINE]
15.

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

Alli E, Sharma VB, Sunderesakumar P, Ford JM.

Cancer Res. 2009 Apr 15;69(8):3589-96. doi: 10.1158/0008-5472.CAN-08-4016. Epub 2009 Apr 7.

PMID:
19351835
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

PMID:
19567590
[PubMed - indexed for MEDLINE]
Free Article
17.

Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.

Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM.

Oncogene. 1998 Apr 30;16(17):2229-41.

PMID:
9619832
[PubMed - indexed for MEDLINE]
Free Article
18.

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.

Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W.

Breast Cancer Res Treat. 2011 Jun;127(3):861-9. doi: 10.1007/s10549-011-1441-2. Epub 2011 Mar 17.

PMID:
21409392
[PubMed - indexed for MEDLINE]
19.

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.

PMID:
18588872
[PubMed - indexed for MEDLINE]
20.

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Drew Y, Plummer R.

Curr Opin Obstet Gynecol. 2010 Feb;22(1):67-71. doi: 10.1097/GCO.0b013e328334ff57. Review.

PMID:
19934756
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk